Background-High-density lipoprotein (HDL) protects the artery wall by removing cholesterol from lipid-laden macrophages.
H igh-density lipoprotein (HDL) protects against vascular disease by removing cholesterol from artery wall macrophages through reverse cholesterol transport. [1] [2] [3] [4] There is mounting evidence, however, that it has additional antiatherosclerotic effects. 2, [5] [6] [7] [8] One such activity may be modulation of the inflammatory response of the innate immune system. 9 -14 
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Two cholesterol-transporting proteins, ABCA1 and ABCG1, might link HDL to both cholesterol removal and regulation of inflammation. 10 -12 Both membrane-associated ATP-binding cassette transporters are found in macrophages. ABCA1 promotes cholesterol efflux to lipid-poor apolipoprotein (apo) A-I, the major HDL protein, and ABCG1 induces cholesterol efflux to intact HDL particles. 10 Macrophages isolated from mice with genetically engineered deficiencies in ABCA1 and/or ABCG1 overexpress well-known inflammatory genes such as tumor necrosis factor-␣ (TNF-␣), interleukin (IL) -1␤, and IL-8 when the cells are stimulated with bacterial lipopolysaccharide (LPS). 11 In both macrophages and endothelial cells, the antiinflammatory effects of HDL have been proposed to reflect changes in membrane cholesterol and lipid rafts, with downstream effects on signal transduction and the activities of membrane-associated proteins. 11, 12, 15 The response of the innate immune system to infection involves membrane-associated Toll-like receptors (TLRs), which can sense a diverse range of conserved microbial structures. 16 TLR signal transduction begins when 1 or more adaptor proteins are recruited to the intracellular TIR (Toll/ interleukin-1 receptor) domain of the receptor. These adaptors include myeloid differentiation primary response protein 88 (MyD88), TIR domain-containing adaptor protein inducing interferon (TRIF), and TRIF-related adapter molecule (TRAM).
The classic TLR ligand is LPS, which rapidly upregulates thousands of macrophage genes. [17] [18] [19] LPS binds to TLR4, which in turn activates signaling pathways dependent on MyD88 or TRAM/TRIF. 20 The MyD88 pathway activates nuclear factor-B and other transcription factors, which in turn induce type II interferon (IFN) response genes such as TNF-␣ and IL-1␤. In contrast, the TRAM/TRIF pathway, which is independent of MyD88, induces the expression of IFN-␤ by activating IFN regulatory factor 3 (Irf3), a transcription factor. 21, 22 IFN-␤ then activates other type I IFNinducible genes. The type II IFN response enhances antibacterial responses by macrophages, whereas the type I IFNs are potent antiviral immunoregulators. 23, 24 We analyzed macrophages with microarrays to search for novel antiinflammatory actions of HDL and possible roles for ABCA1 and/or ABCG1. We found that HDL exerts potent effects on the type I IFN pathway in LPS-stimulated macrophages without assistance from cholesterol transporters. These observations raise the possibility that therapies that raise HDL levels might act in novel ways to retard atherosclerosis and perhaps other immune disorders.
Methods
For additional details, see the online-only Data Supplement.
Cell Culture
Macrophages were isolated by lavage from the peritoneum of C57BL/6 mice 5 days after intraperitoneal injection of thioglycolate, adhesion purified, and cultured in Dulbecco minimum essential medium supplemented with 2% lipoprotein-deficient bovine serum (Sigma, St Louis, Mo). After incubation for 48 hours with or without 50 g/mL acetylated low-density lipoprotein (LDL) in 2% lipoprotein-deficient bovine serum in Dulbecco minimum essential medium, macrophages were treated for 4 hours with serum-free medium supplemented with or without 50 g/mL HDL and then exposed for 4 hours to serum-free medium supplemented with or without 100 ng/mL LPS.
Microarray Analysis
All microarray data are available from the Gene Expression Omnibus Database (accession number GSE19340).
TRAM Translocation
RAW264.7 macrophage cells were stably transfected with retrovirus expressing TRAM-GFP. 25 Cells were treated with serum-free medium supplemented with HDL or LDL (50 g/mL) for 4 hours. The subcellular location of TRAM-GFP was determined by fluorescence microscopy.
Murine Infection Model
Mice were housed under specific pathogen-free conditions. 26 C57BL/6 mice and apoA-I-deficient C57BL/6 mice 27 were injected intraperitoneally with 500 colony-forming units of log-phase Salmonella typhimurium in 0.2 mL PBS. Animals were matched for gender, weight, and age.
Statistical Analysis
Data are given as means and SEMs. Comparison of mean values between 2 groups was evaluated by the 2-tailed Student t test. With Ͼ2 groups, we used the Kruskal-Wallis (nonparametric ANOVA) with the Wilcoxon signed-rank test for comparisons posttest. Differences were considered significant at PϽ0.05. Unless otherwise indicated, nϭ3 per group.
Results
To test the hypothesis that HDL can suppress inflammatory pathways triggered by TLRs, we first exposed cholesterolladen macrophages to medium alone or medium supplemented with mouse HDL (50 g/mL protein), extensively washed the cells, and then challenged them with the LPS (100 ng/mL), a TLR4 ligand ( Figure 1A ). To determine how HDL affected gene expression, we used transcriptional profiling.
HDL Selectively Inhibits LPS-Induced Genes That
Are Turned on by the TRAM/TRIF-Dependent Signaling Pathway
In 2 independent experiments with 4 biological replicates per group, 2749 of 28 289 genes showed statistically significant differential expression in macrophages challenged with LPS (false discovery rate controlled at level 0.05). We observed particularly striking increases (Ͼ10-fold; Table I in the onlineonly Data Supplement) in levels of messenger RNA (mRNA) for cytokines (Il-1␤, Tnf-␣, Il-6, and Il-12␤) and chemokines (Ccl4, Ccl5, Cxcl2, Cxcl3, and Cxcl10). Using the criterion of a significant change in gene expression that was at least 1.5-fold, we observed 911 genes that were regulated by LPS. There was extensive overlap between the genes regulated by LPS (100 ng/mL) in our study and those reported by investigators using a lower LPS concentration (10 ng/mL). 19 We next explored the effect of HDL on LPS-induced gene expression. Pretreatment of macrophages with HDL prevented (by Ն25%) LPS from inducing 277 genes (Tables II  and III in the online-only Data Supplement). Strikingly, the most strongly affected genes ( Figure 1B ) were viral response genes known to be induced by the TRAM/TRIF-dependent pathway. 19, 28 Examples were Irf7, Cxcl10 (IP-10), Il-12␤, Il-15, Tlr3, Tlr8, Nos2 (inducible nitric oxide synthase), Ifit1, and Ifit3 ( Figure 1B ). In contrast, HDL pretreatment failed to significantly suppress MyD88-dependent pathway genes such as Tnf-␣, Il-6, and Il-1␤ ( Figure 1B) .
Using gene ontology, we characterized cellular processes affected by HDL pretreatment. Gene ontology analysis with the DAVID algorithm 29 demonstrated a significant enrichment (relative to the entire mouse genome) in "response to virus" genes (Pϭ9ϫ10 Ϫ14 ; Table III in the online-only Data Supplement), whereas "Inhibitor of B kinase/nuclear factor-B cascade" genes activated by LPS were not significantly different (Table III in the online-only Data Supplement). These results suggest that exposing macrophage foam cells to HDL suppresses the subsequent expression of a subset of genes that are regulated by LPS through the TRAM/TRIF pathway that do not involve MyD88, the type I IFN pathway. 23, 30 We used quantitative reverse-transcription polymerase chain reaction (qRT-PCR) to quantify mRNA levels for 6 important genes in this pathway: Irf7, Ip-10, Il-12b, Tlr3, Tlr8, and Il-15. All are activated by the TRAM/TRIF pathway when cells are challenged with TLR4 agonists. 23, 24 Five of the 6 genes (Irf7, Ip-10, Il-12b, Tlr3, and Il-15) were significantly induced by LPS (PϽ0.05; Figure 1C ). However, increased gene expression was almost completely abrogated by pretreating macrophages with HDL ( Figure 1C ). The inhibitory effect of HDL depended on its concentration in the medium ( Figure I in the online-only Data Supplement). Effect of HDL pretreatment on TRAM/TRIF-dependent and MyD88-dependent genes in cholesterol-laden mouse macrophages challenged with LPS. A, Experimental approach. Thioglycolate-elicited peritoneal macrophages were isolated from mice, adhesion purified, and incubated for 48 hours with acetylated LDL in 2% lipoprotein-deficient bovine serum. Macrophages were treated for 4 hours with serum-free medium or serum-free medium supplemented with 50 g/mL mouse HDL, washed, and then exposed for 4 hours to serum-free medium or serum-free medium supplemented with 100 ng/mL LPS. B, Array analysis of LPS-stimulated macrophages. RNA harvested from LPS-stimulated macrophages, with or without HDL pretreatment, was analyzed on microarrays. 
HDL Inhibits LPS-Stimulated Secretion of IFN-␤, IFN-Inducible Protein-10, and IL-12 From Macrophages
To determine whether our mRNA data were paralleled at the protein level, we monitored levels of IFN-␤, IFN-inducible protein-10 (IP-10), and IL-12␤ in macrophage-conditioned medium. LPS stimulated the expression of IFN-␤ (7-fold), IP-10 (Ͼ1000-fold), and IL-12␤ (1000-fold) protein. IFN-␤ was readily detected in media harvested from LPS-stimulated cells but was undetectable by our assay in 2 of the 3 control cell media and in 1 of 3 media from HDL-pretreated cells ( Figure 1D ). HDL significantly lowered levels of IP-10 and IL-12␤ in the medium of macrophages challenged with LPS ( Figure 1D ). These data indicate that at both the mRNA and protein levels, HDL suppresses TRIM/TRAM pathway genes in macrophages challenged with LPS.
HDL Inhibits TLR4 Agonist-Induced Genes That Are Turned on by the TRAM/TRIF Pathway
To explore how HDL affects the TRIM/TRAM pathway, we determined whether pretreating macrophages with HDL prevented a TLR4 agonist antibody from regulating gene expression. Irf7, Ip-10, and Tnf-␣ were all induced when the macrophages were incubated with the antibody (Figure 2 ). Pretreating the macrophages with HDL significantly inhibited the expression of the TRAM/TRIF-dependent pathway genes Irf7 and Ip-10. Thus, HDL suppresses activation of the TRIM/TRAM pathway when TLR4 is activated by a lipid (LPS) or protein (antibody) agonist.
The Suppressive Effects of HDL Do Not Require LPS to Bind Lipoproteins
It is well established that HDL, LDL, and other lipoproteins bind to LPS to prevent it from activating TLR4. 31, 32 To determine whether this mechanism is responsible for the ability of HDL to inhibit gene expression, we exposed macrophages to HDL or LDL and quantified the LPS-induced expression of Irf7 and Ip-10 (2 TRAM/TRIF-dependent genes) and Tnf-␣ (an MyD88-dependent pathway gene). LPS significantly increased the expression of all 3 genes (PϽ0.001; Figure 3 ): Irf7 (20-fold), Ip-10 (500-fold), and Tnf-␣ (100-fold). HDL suppressed this induction of Irf7 and Ip-10 but did not significantly affect Tnf-␣ expression (Figure 3 ). In contrast, the same concentration of human LDL (50 g/mL protein) had little effect on gene expression (Figure 3) .
When macrophages were challenged with a 10-fold lower concentration of LPS (10 ng/mL), pretreatment with HDL inhibited the induction of Irf7 but not of TNF-␣ ( Figure III in the online-only Data Supplement). These results do not support the hypothesis that HDL selectively inhibits type 1 IFN response genes because the TRAM/TRIF pathway is more sensitive than the MyD88 pathway to lower concentrations of LPS.
Next, we considered the possibility that HDL might inhibit LPS activity by binding to and sequestering CD14 or TLR4 on the cell surface. 
Inhibition of TRAM/TRIF-Dependent Genes by HDL Is Independent of Macrophage Cholesterol Content
Previous work strongly supports the proposal that HDL decreases the inflammatory state of macrophages by enabling ABCA1 or ABCG1 to remove excess cellular sterol. 10, 11 To determine whether these transporters are involved when HDL suppresses genes in the TRAM/TRIF-dependent pathway, we downregulated ABCA1 and ABCG1 using small interfering RNA (Figure 4 ). Immunoblot analysis confirmed decreased protein expression ( Figure 4A ). However, HDL pretreatment suppressed LPS-induced expression of Irf7 or Ip-10 to the same extent ( Figure 4B ). Thus, the suppressive effect of HDL is not mediated through ABCA1 or ABCG1, and its antiinflammatory properties appear to be independent of cholesterol stores. We next depleted macrophages of cholesterol by treating them for 4 hours with ␤-methylcyclodextrin. 33 ␤-Methylcyclodextrin pretreatment did not alter the ability of HDL to suppress LPS-induced Irf7 or Il-12b induction ( Figure 5A ), and ␤-methylcyclodextrin itself did not inhibit LPS response ( Figure  5B ). We also determined whether lipid-free apoA-I, the major protein of HDL, would suppress LPS-stimulated gene expression. We first showed that a 4-hour incubation with 10 g/mL apoA-I promoted cholesterol efflux from acetylated LDLloaded macrophages to about the same extent as 50 g/mL HDL. Then we demonstrated that 10 g/mL apoA-I did not significantly affect the ability of LPS to induce the expression of Irf7 ( Figure 5C ).
To further investigate the role of cholesterol loading, we performed microarray analysis on macrophages that had been incubated for 48 hours with either 2% lipoprotein-deficient serum or serum alone supplemented with 50 g/mL acetylated LDL. HDL inhibited the expression of LPS-induced genes in the TRAM/TRIF-dependent pathway to a similar degree under both conditions ( Figure 5D ). Thus, cholesterol loading or depletion has little effect on the ability of HDL to suppress genes in the TRAM/TRIF-dependent pathway when macrophages are challenged with LPS.
HDL Suppresses IFN Pathway Genes Through TLR4 but Not Through TLR2, TLR3, TLR7/8, or CD14
We used poly I:C (a TLR3 ligand) and R848 (a TLR7/8 ligand) to determine whether HDL specifically suppresses the TLR4 pathway. Each ligand induced macrophages to express representative type I and type II IFN response genes: Irf7, iNOS, Ip-10, Il-15, and Il-12␤ ( Figure 6 ). However, HDL pretreatment suppressed those genes significantly only when the macrophages were challenged with LPS (PϽ0.05 for all conditions). Thus, the ability of HDL to inhibit gene expression in macrophages appears to be specific for LPS and a TLR4 agonist antibody, strongly suggesting that it selectively affects TLR4 signaling.
Because HDL acted on the TLR4 signaling pathway, we wondered if CD14, a key regulator of both the MyD88-independent and -dependent pathways, was its target. 34 We found, however, that HDL had no effect on TLR2 signaling ( Figure VI in the online-only Data Supplement), which also involves CD14. Moreover, HDL also failed to affect CD14 expression in macrophages (as measured by flow cytometry), and soluble CD14 was unable to overcome the suppressive action of HDL (data not shown). Thus, CD14 does not appear to be involved in the action of HDL on innate immunity genes.
HDL Induces TRAM Translocation to Intracellular Compartments
Recent studies suggest that TLR4 activates the TRAM/TRIF pathway by signaling from early endosomes. 25, 35 The proposed mechanism involves LPS-induced endocytosis of TLR and then TRAM/TRIF-dependent signaling from an endosomal compartment. To determine whether this pathway might be involved when HDL regulates type 1 IFN response genes, we used a macrophage cell line stably transfected with a TRAM-GFP fusion protein. 25 When macrophages were incubated for 4 hours in serumfree medium (Figure 7 ) or medium supplemented with 2% FBS (data not shown), fluorescence microscopy demonstrated that virtually all of the TRAM-GFP fusion protein was associated with the plasma membrane of the macrophages. However, cells incubated with 50 g/mL HDL translocated TRAM to intracellular compartments ( Figure 7 ) but did not induce Irf7 (data not shown). LDL failed to affect the cellular location of TRAM (Figure 7 ). These observations suggest that HDL induces TRAM translocation to endosomes or other intracellular compartments, which might account for the impairment in TLR4 signaling. Suppressive effects of HDL in LPS-stimulated cholesterol-laden macrophages exposed to small interfering RNAs for ABCA1 or ABCG1. Isolated macrophages were incubated with 2% lipoprotein-deficient bovine serum and transfected with specific small interfering RNA for 24 hours to knock down ABCA1 and ABCG1. Macrophages were then loaded with cholesterol by changing the medium to 2% lipoprotein-deficient bovine serum supplemented 50 g protein/mL acetylated LDL. A, Immunoblot analysis. Cellular lysates were fractionated on a 5% to 15% gradient SDS-PAGE and then subjected to immunoblot analysis with antibodies to ABCA1 or ABCG1. B, qRT-PCR analysis. *PϽ0.05 vs no HDL and no LPS stimulation; #PϽ0.05 vs no HDL and LPS stimulation by the Kruskal-Wallis test. Results are representative of 2 independent experiments.
Plasma IFN-␤ Levels Increase Markedly in ApoA-I-Deficient Mice Challenged With S typhimurium
To determine whether HDL prevents LPS from inducing TRAM/TRIF genes in vivo, we infected wild-type and apoA-I-deficient mice (both in the C57BL/6 background) with S typhimurium, a Gram-negative bacterium that expresses LPS. HDL cholesterol levels in the apoA-Ideficient mice were Ϸ20% those in the wild-type mice ( Figure 8A ). By 10 days after the bacterial challenge, the same number of animals in each group had died (8 of 10; Figure 8B ), suggesting that apoA-I deficiency did not significantly affect survival. In striking contrast, plasma levels of IFN-␤ were 6-fold greater in the apoA-I-deficient mice, even though the 2 strains had similar plasma levels of TNF-␣ ( Figure 8C ). Thus, HDL appeared to selectively modulate the expression of IFN-␤, a key mediator of the type I IFN response, in this model of Gram-negative sepsis.
Discussion
Our observations indicate that HDL selectively prevents the activation of type I IFN response genes when macrophages are challenged with LPS, the classic TLR4 ligand, or a TLR4 agonist antibody. In contrast, HDL has little effect on gene expression triggered by ligands for TLR2, TLR3, or TLR7/8. Although previous studies have demonstrated that cholesterol accumulation in the plasma membrane of macrophages deficient in ABCA1 and/or ABCG1 promotes TLR4 signaling and the expression of inflammatory genes (eg, TNF-␣, 11, 12 we found that HDL suppressed the type I IFN response regardless of whether macrophages were loaded with cholesterol or ABCA1 or ABCG1 expression was inhibited. Our observations suggest that regulation of the type I IFN response in macrophages might contribute to the cardioprotective and antiinflammatory effects of HDL by mechanisms that do not involve sterol metabolism.
IL-6),
The type I IFN response is triggered when IFN-␤ is upregulated by TLR4-dependent activation of the transcription factor Irf7. 21, 22 We found that plasma levels of IFN-␤ were greater in apoA-I-deficient mice than in wild-type mice when the animals were challenged with S typhimurium, a Gram-negative bacterium that expresses LPS. In contrast, the 2 mouse strains had similar plasma levels of TNF-␣, suggesting that HDL regulates the type I IFN response but not the type II response in this model of infection. Regulation of the innate immune system might also contribute to the cardioprotective effects of HDL.
Using ligands specific for the various TLRs, we showed that HDL selectively inhibits the expression of type I IFN response genes regulated by TLR4. Moreover, those genes appear to require the adaptor proteins TRAM and TRIF (but not MyD88) for signaling. 36 Thus, we found that HDL failed to inhibit cytokine and chemokine expression by poly I:C, a TLR3 ligand for a pathway requiring TRIF but not TRAM. In contrast, signaling by TLR4 requires both TRAM and TRIF. The simplest interpretation is that HDL inhibits TLR4 signaling at a step before TRIF, possibly by a mechanism involving TRAM. Because the ability of HDL to inhibit TLR4 signaling appeared little affected by macrophage sterol balance, the underlying mechanism is unlikely to be regulated directly by cholesterol.
Signaling by TRAM requires endocytosis of TLR4. 25, 35 We found that TRAM translocates to intracellular compartments when macrophages are treated with HDL and that translocated TRAM cannot induce Irf7 expression. In contrast, LDL failed to change the cellular location of TRAM. These observations suggest that HDL induces TRAM translocation to an intracellular compartment, thereby impairing subsequent signaling by TLR4. We therefore propose that HDL depletes the plasma membrane of TRAM, a key adaptor molecule that activates TRIF in endosomal compartments.
Recent observations support our suggestion that the TLR4/ TRAM/TRIF signaling cascade in macrophages is regulated at a step proximal to TRIF. In mice, Wang et al 37 found that a deficiency in the hemochromatosis gene, Hfe, also suppresses the expression of TRAM/TRIF-dependent genes by a pathway that requires TLR4 but not TLR3.
It is possible that activation of the type I IFN response in macrophages contributes to atherogenesis. For example, TLR4 deficiency reduces atherosclerosis in hypercholesterolemic mice, 38 suggesting that ligands for this receptor activate macrophages in atherosclerotic lesions. Moreover, TLR4 signaling via TRAM/TRIF induces the type I IFN response gene Cxcl10 (IP-10), a T-cell chemokine. 39 IP-10 is highly expressed in murine and human atherosclerotic tissue, 40 and lesion formation is retarded in hypercholesterolemic mice deficient in IP-10 or its receptor. 41 Type I IFNs play a critical role in the antiviral response of cells. 42 A key component of the system is a feed-forward loop, which amplifies the initial response to the invading virus. However, positive feedback is deleterious when the response is excessive. 43 HDL may be a physiologically relevant regulator of amplification because an apoA-I mimetic peptide, D-4F, reduced viral lung titers and tissue inflammation in mice infected with influenza virus. 44 In cultured cells infected with virus, D-4F suppressed secretion of IFN-␣ and IFN-␤, suggesting inhibition of the type I IFN response. 45 Moreover, type I IFNs promote disease amplification in autoimmune rheumatologic disorders, 43 and apoA-I regulates T-cell activation in hypercholesterolemic mice. 46 These observations raise the possibility that HDL controls inflammation during infection and the immune response against host tissue.
Classically, the type I IFN response produces potent antiviral immunoregulators 24 and the type II response promotes antibacterial activities of macrophages. 42 However, emerging evidence also implicates the type I IFN response in host defense during bacterial infection. 23 Our observations are consistent with previous suggestions that HDL regulates the cellular response to viral infection. 44, 45, 47 These observations raise the possibility that HDL controls inflammation during infection and the immune response against host tissue.
